Author(s)
Kiltz U1, Perez-Ruiz F2, Uhlig T3, Jansen TL4, Karra R5, Schmedt N6, Galetzka W6, Petersen G5, Schönfelder T7, Tausche A8
1Rheumazentrum Ruhrgebiet, Herne, Germany, 2BioCruces Health Research Institute, Barakaldo, Spain, 3Institute of Clinical Medicine, Oslo, Norway, 4VieCuri Medisch Centrum, Venlo, The Netherlands, 5Grünenthal GmbH, Aachen, Germany, 6InGef – Institute for Applied Health Research Berlin, Berlin, Germany, 7inav - Institute for Applied Health Services Research, Berlin, Germany, 8Technische Universität Dresden, Dresden, Germany
OBJECTIVES: Gout is the most common inflammatory arthritis in Germany. This study aimed to provide an up-to-date analysis on the prevalence and incidence of gout, associated comorbidities, current treatment patterns, as well as health ressource use (HRU) and costs METHODS: The InGef database of ~4 million healthcare claims, was used. Patients were included based on hospital discharge/ambulatory diagnoses of gout (ICD10 M10)/ hyperuricemia (E79.0) in combination with uric acid tests, prescription of urate lowering therapy (ULT), and treatment of gout flare. Prevalent cases were analyzed for comorbidities, treatments, HRU, and costs. Data of gout patients were compared to an age- and sex-matched control group without gout RESULTS: Prevalence was 1.63% corresponding to 1.3 million patients, incidence was 0.45%. Approximately 46.7% of patients were in the working age group of <65 years. Gout patients had more comorbidities, hospitalizations, physician’ and specialist’ visits, and medications than patients without gout (p<0.001). Mean hospital costs were higher (gout patients: 2,498€ vs. non-gout patients: 1,667€), as well as drug treatment costs (1,148€ vs. 815€), ambulatory care costs (971€ vs. 722€), and costs for remedies and aids (427€ vs. 332€) (p<0.001). Consequently, overall mean costs were significantly higher in gout patients (5,193€) as compared to patients without gout (3,642€) (p<0.001). Also gout patients took ~20% more sick leave than non-gout patients (6.93 vs. 4.63 days) CONCLUSIONS: Gout is highly prevalent and associated with a higher number of comorbidities, physician visits and medications, with substantially increased health resource use and overall costs, as well as a higher number of sick leave days, compared to patients without gout
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
DS1
Topic
Economic Evaluation, Health Service Delivery & Process of Care
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Hospital and Clinical Practices, Prescribing Behavior
Disease
Musculoskeletal Disorders
Explore Related HEOR by Topic
